دورية أكاديمية
أعرض في EDS

Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial.

التفاصيل البيبلوغرافية
العنوان: Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial.
المؤلفون: González-Hernández LA; HIV Unit Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara, Calle Hospital 278, Colonia Alcalde Barranquitas, Guadalajara, Jalisco, 44280, Mexico., Jave-Suarez LF, Fafutis-Morris M, Montes-Salcedo KE, Valle-Gutierrez LG, Campos-Loza AE, Enciso-Gómez LF, Andrade-Villanueva JF
المصدر: Nutrition journal [Nutr J] 2012 Oct 29; Vol. 11, pp. 90. Date of Electronic Publication: 2012 Oct 29.
نوع المنشور: Comparative Study; Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101152213 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2891 (Electronic) Linking ISSN: 14752891 NLM ISO Abbreviation: Nutr J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2002-
مواضيع طبية MeSH: Bacterial Translocation* , Prebiotics*/adverse effects , Probiotics*/adverse effects , Probiotics*/isolation & purification, Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use , HIV Enteropathy/*diet therapy , Intestinal Mucosa/*microbiology, Adult ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Bifidobacterium/classification ; Bifidobacterium/growth & development ; Bifidobacterium/immunology ; Bifidobacterium/isolation & purification ; CD4 Lymphocyte Count ; Cytokines/blood ; Cytokines/metabolism ; DNA, Bacterial/blood ; Disease Progression ; Double-Blind Method ; Feces/microbiology ; Female ; HIV Enteropathy/immunology ; HIV Enteropathy/microbiology ; HIV Enteropathy/physiopathology ; Humans ; Intestinal Mucosa/immunology ; Intestinal Mucosa/physiopathology ; Lacticaseibacillus rhamnosus/classification ; Lacticaseibacillus rhamnosus/growth & development ; Lacticaseibacillus rhamnosus/immunology ; Lacticaseibacillus rhamnosus/isolation & purification ; Male ; Mexico ; Pilot Projects ; Quality of Life ; Young Adult
مستخلص: Background: HIV-infection results in damage and dysfunction of the gastrointestinal system. HIV enteropathy includes pronounced CD4+ T-cell loss, increased intestinal permeability, and microbial translocation that promotes systemic immune activation, which is implicated in disease progression. A synbiotic is the combination of probiotics and prebiotics that could improve gut barrier function. Our study goal was to determine whether the use of a synbiotic, probiotics or a prebiotic can recover immunological parameters in HIV-infected subjects through of a reduction of microbial translocation and pro-inflammatory cytokine production.
Methods: A randomized, double-blind controlled study was performed; twenty Antiretroviral treatment-naïve HIV-infected subjects were subgrouped and assigned to receive a synbiotic, probiotics, a prebiotic, or a placebo throughout 16 weeks.
Results: We had no reports of serious adverse-events. From baseline to week 16, the synbiotic group showed a reduction in bacterial DNA concentrations in plasma (p = 0.048). Moreover, the probiotic and synbiotic groups demonstrated a decrease in total bacterial load in feces (p = 0.05). The probiotic group exhibited a significant increment of beneficial bacteria load (such as Bifidobacterium; p = 0.05) and a decrease in harmful bacteria load (such as Clostridium; p = 0.063). In the synbiotic group, the CD4+ T-cells count increased (median: +102 cells/μL; p = 0.05) and the level of Interleukin 6 cytokine decreased significantly (p = 0.016).
Conclusions: Our study showed a significant increase in CD4+ T lymphocyte levels in the synbiotic group, which could delay the initiation of antiretroviral therapy and decrease costs in countries with limited resources.
References: Br J Nutr. 2008 Feb;99(2):254-61. (PMID: 17711612)
Curr Opin HIV AIDS. 2006 Jan;1(1):3-9. (PMID: 19372776)
Food Chem Toxicol. 1998 Dec;36(12):1085-94. (PMID: 9862651)
HIV Clin Trials. 2004 Jul-Aug;5(4):183-91. (PMID: 15472792)
J Clin Gastroenterol. 2008 Mar;42(3):239-43. (PMID: 18223503)
Nutrition. 2003 Jul-Aug;19(7-8):657-60. (PMID: 12831954)
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S67-72; discussion S144-51. (PMID: 18181726)
J Exp Med. 2004 Sep 20;200(6):749-59. (PMID: 15365096)
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S104-11; discussion S144-51. (PMID: 18181712)
J Trop Pediatr. 2008 Feb;54(1):19-24. (PMID: 17878180)
Top HIV Med. 2009 Apr-May;17(2):57-67. (PMID: 19401608)
Clin Microbiol Infect. 2005 Dec;11(12):958-66. (PMID: 16307549)
Mucosal Immunol. 2008 Jan;1(1):23-30. (PMID: 19079157)
J Infect Dis. 2003 May 15;187(10):1534-43. (PMID: 12721933)
Mol Nutr Food Res. 2005 Jun;49(6):609-19. (PMID: 15864790)
J Virol. 2006 Aug;80(16):8236-47. (PMID: 16873279)
Appl Environ Microbiol. 2004 Dec;70(12):7220-8. (PMID: 15574920)
J Agric Food Chem. 2003 Dec 31;51(27):7835-40. (PMID: 14690361)
Nat Med. 2006 Dec;12(12):1365-71. (PMID: 17115046)
Curr Opin HIV AIDS. 2010 Mar;5(2):189-93. (PMID: 20543599)
AIDS. 2007 Jan 2;21(1):1-11. (PMID: 17148962)
Curr Opin HIV AIDS. 2008 May;3(3):356-61. (PMID: 19372990)
Am J Clin Nutr. 2006 Jun;83(6):1256-64; quiz 1446-7. (PMID: 16762934)
Microbiol Res. 2008;163(6):663-70. (PMID: 19216105)
PLoS Med. 2008 Oct 21;5(10):e203. (PMID: 18942885)
AIDS Rev. 2010 Jan-Mar;12(1):15-30. (PMID: 20216907)
J Infect Dis. 2009 Apr 15;199(8):1177-85. (PMID: 19265479)
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S87-91; discussion S144-51. (PMID: 18181730)
Top HIV Med. 2009 Jul-Aug;17(3):98-103. (PMID: 19675367)
HIV Clin Trials. 2005 Jul-Aug;6(4):203-12. (PMID: 16323322)
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S58-61; discussion S144-51. (PMID: 18181724)
Gastroenterology. 2008 Feb;134(2):577-94. (PMID: 18242222)
Nat Immunol. 2006 Mar;7(3):235-9. (PMID: 16482171)
AIDS. 2007 Nov 30;21(18):2377-85. (PMID: 18025874)
Am J Gastroenterol. 2000 Apr;95(4):999-1007. (PMID: 10763950)
Int Rev Immunol. 2010 Oct;29(5):485-513. (PMID: 20839912)
J Exp Med. 2004 Sep 20;200(6):761-70. (PMID: 15365095)
J Appl Microbiol. 2006 Jun;100(6):1171-85. (PMID: 16696665)
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S80-6; discussion S144-51. (PMID: 18181729)
AIDS. 2005 Jan 28;19(2):107-17. (PMID: 15668535)
المشرفين على المادة: 0 (Anti-Inflammatory Agents, Non-Steroidal)
0 (Cytokines)
0 (DNA, Bacterial)
0 (Prebiotics)
تواريخ الأحداث: Date Created: 20121030 Date Completed: 20130412 Latest Revision: 20221207
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3494555
DOI: 10.1186/1475-2891-11-90
PMID: 23101545
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2891
DOI:10.1186/1475-2891-11-90